

## Department of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

September 13, 2022: 6:00 – 8:30 p.m.

	7	
•	Executive Session	6:00 - 6:30
•	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	6:30 - 6:35
•	Election of DUR Board Chair	6:35 - 6:40
•	<b>DVHA Pharmacy Administration Updates</b>	6:40 - 6:45
•	Chief Medical Officer Updates	6:45 - 6:50
•	Follow-up Items from Previous Meetings	6:50 - 6:55
•	RetroDUR/ProDUR  Data presentation: Opioid Use from Multiple Providers Introduce: Proposed RetroDUR topics for 2023	6:55- 7:20
•	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:20-7:55

## **Biosimilar Drug Reviews**

None at this time.

## **Full New Drug Reviews**

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Dartisla® ODT (glycopyrrolate)
- Fleqsuvy® (baclofen oral suspension) and Lyvispah® (baclofen granules for oral suspension)
- Leqvio® (inclisiran)
- Seglentis® (celecoxib and tramadol hydrochloride)
- Tarpeyo® (budesonide)

## New Managed Therapeutic Drug Classes

7:55 -7:55

None at this time

(Public comment prior to Board action)

None at this time

-	General Announcements	8:30 - 8:30
•	Review of Newly Developed/Revised Criteria (Public comment prior to Board action)  - 2022/23 Influenza Vaccines	8:25 - 8:30
	<ul> <li>Ulcerative Colitis (non-biologic oral and rectal agents)</li> </ul>	

Dependency (new drug Zimhi® (naloxone HCI) included)

Analgesics: NSAIDs (new drug Lofena® (diclofenac potassium) and Elyxyb®

Opioid Dependency, Opioid withdrawal treatment, Overdose Treatment, and Alcohol

7:55 - 8:25

8:30

**Therapeutic Drug Classes – Periodic Review** 

Allergen Extract Immunotherapy

Analgesics: Topical Anesthetics

(Public comment prior to Board action)

(celecoxib) included)

Iron Chelating Agents

Otic Anti-infectives Phosphate Binders

Adjourn